Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillarassociated protein 4 in hepatitis C patients
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs. Methods: MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up (FU) visit. Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed. Results: MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R²=0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon P<0.001 for both). Conclusions: Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.
Abstract
Background/Aims: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs. Methods: MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up (FU) visit. Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed. Results: MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R²=0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon P<0.001 for both). Conclusions: Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.
참고문헌 (45)
- Gower E, "Global epidemiology and genotype distribution of the hepatitis C virus infection", J Hepatol, 61(1 Suppl), pp.S45~S57 (2014)
- Lerat H, "Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus", Gastroenterology, 122, pp.352~365 (2002)
- Perlemuter G, "Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion : a model of viral-related steatosis", FASEB J, 16, pp.185~194 (2002)
- Moriya K, "Hepatitis C virus core protein induces hepatic steatosis in transgenic mice", J Gen Virol, 78(Pt 7), pp.1527~1531 (1997)
- Gong G, "Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B", Proc Natl Acad Sci U S A, 98, pp.9599~9604 (2001)
- Friedman SL, "Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury", J Biol Chem, 275, pp.2247~2250 (2000)
- Bissell DM, "Chronic liver injury, TGF-beta, and cancer", Exp Mol Med, 33, pp.179~190 (2001)
- Gressner AM, "Roles of TGFbeta in hepatic fibrosis", Front Biosci, 7, pp.d793~d807 (2002)
- McCrudden R, "Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases", Histol Histopathol, 15, pp.1159~1168 (2000)
- Knittel T, "Rat liver myofibroblasts and hepatic stellate cells : different cell populations of the fibroblast lineage with fibrogenic potential", Gastroenterology, 117, pp.1205~1221 (1999)
- Suou T, "Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa", Hepatology, 22, pp.426~431 (1995)
- Hiramatsu N, "Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha", J Hepatol, 22, pp.135~142 (1995)
- Dore GJ, "Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward)", J Viral Hepat, 21(Suppl 1), pp.1~4 (2014)
- Dore GJ, "Hepatitis C virus therapeutic development : in pursuit of"perfectovir"", Clin Infect Dis, 60, pp.1829~1836 (2015)
- Thomas DL, "Curing hepatitis C with pills : a step toward global control", Lancet, 376, pp.1441~1442 (2010)
- Hill A, "Medicine. Hepatitis C can be cured globally, but at what cost?", Science, 345, pp.141~142 (2014)
- Knop V, "Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy", J Viral Hepat, 23, pp.994~1002 (2016)
- Mölleken C, "Detection of novel biomarkers of liver cirrhosis by proteomic analysis", Hepatology, 49, pp.1257~1266 (2009)
- Bracht T, "Analysis of disease-associated protein expression using quantitative proteomics--fibulin-5 is expressed in association with hepatic fibrosis", J Proteome Res, 14, pp.2278~2286 (2015)
- Wulf-Johansson H, "Localization of microfibrillar-associated protein 4(MFAP4)in human tissues : clinical evaluation of serum MFAP4 and its association with various cardiovascular conditions", PloS One, 8, pp.e82243~ (2013)
- Pilecki B, "Characterization of microfibrillar-associated protein 4(MFAP4)as a tropoelastin-and fibrillin-binding protein involved in elastic fiber formation", J Biol Chem, 291, pp.1103~1114 (2016)
- Schlosser A, "MFAP4 promotes vascular smooth muscle migration, proliferation and accelerates neointima formation", Arterioscler Thromb Vasc Biol, 36, pp.122~133 (2016)
- Pilecki B, "Microfibrillar-associated protein 4 modulates airway smooth muscle cell phenotype in experimental asthma", Thorax, 70, pp.862~872 (2015)
- Lock-Johansson S, "Surfactant protein D, club cell protein 16, pulmonary and activation-regulated chemokine, Creactive protein, and fibrinogen biomarker variation in chronic obstructive lung disease", Respir Res, 15, pp.147~ (2014)
- Hemstra LE, "Microfibrillarassociated protein 4 variation in symptomatic peripheral artery disease", J Transl Med, 16, pp.159~ (2018)
- Blindbæk SL, "Association between microfibrillar-associated protein 4(MFAP4)and micro-and macrovascular complications in long-term type 1 diabetes mellitus", Acta Diabetol, 54, pp.367~372 (2017)
- Sækmose SG, "Microfibrillar-associated protein 4 : a potential biomarker for screening for liver fibrosis in a mixed patient cohort", PloS One, 10, pp.e0140418~ (2015)
- Bracht T, "Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients", J Transl Med, 14, pp.201~ (2016)
- Sækmose SG, "Enzyme-linked immunosorbent assay characterization of basal variation and heritability of systemic microfibrillarassociated protein 4", PloS One, 8, pp.e82383~ (2013)
- Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
- Alberti A, "Natural history of hepatitis C", J Hepatol 1999;31 Suppl, 31(Suppl 1), pp.17~24 (1999)
- Ghany MG, "Diagnosis, management, and treatment of hepatitis C : an update", Hepatology, 49, pp.1335~1374 (2009)
- Mengshol JA, "Mechanisms of disease : HCV-induced liver injury", Nat Clin Pract Gastroenterol Hepatol, 4, pp.622~634 (2007)
- D’Ambrosio R, "Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon", PloS One, 11, pp.e0155967~ (2016)
- Sebastiani G, "Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases", J Viral Hepat, 15, pp.212~218 (2008)
- Reichard O, "Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon", J Hepatol, 30, pp.783~787 (1999)
- Shiratori Y, "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy", Ann Intern Med, 132, pp.517~524 (2000)
- Poynard T, "Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C", Gastroenterology, 122, pp.1303~1313 (2002)
- Arif A, "Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin", Dig Dis Sci, 48, pp.1425~1430 (2003)
- Pol S, "Reversibility of hepatitis C virus-related cirrhosis", Hum Pathol, 35, pp.107~112 (2004)
- Valva P, "Chronic hepatitis C virus infection : serum biomarkers in predicting liver damage", World J Gastroenterol, 22, pp.1367~1381 (2016)
- Mallet V, "Brief communication : the relationship of regression of cirrhosis to outcome in chronic hepatitis C", Ann Intern Med, 149, pp.399~403 (2008)
- European Association for the Study of the Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Aleman S, "A risk for hepatocellular carcinoma persists longterm after sustained virologic response in patients with hepatitis Cassociated liver cirrhosis", Clin Infect Dis, 57, pp.230~236 (2013)
- Cardoso AC, "Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma : incidence and survival in hepatitis C patients with advanced fibrosis", J Hepatol, 52, pp.652~657 (2010)